Articlenpj drug discovery2026
Interaction-constrained 3D molecular generation using a diffusion model enables structure-based pharmacophore modeling for drug design.
Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A key challenge in structure-based drug design is generating three-dimensional molecules while preserving essential protein-ligand interactions. We propose DiffPharma, a structure-based pharmacophore modeling framework based on a conditional diffusion model, to generate molecules that satisfy specified interaction constraints. The proposed method incorporates a semantic fusion architecture that integrates multiple interaction-specific neural networks, each designed to capture distinct molecular interactions such as hydrogen bonds and hydrophobic interactions. Experimental results demonstrate that DiffPharma achieves a residue-level interaction similarity of up to 0.9, significantly outperforming baseline models. To assess the method's generalizability, ligands were generated for AKT serine/threonine kinase 1 and serine β-lactamase, successfully preserving key interaction features. The effectiveness of the method is demonstrated through a practical case study targeting the SARS-CoV-2 main protease. Molecular dynamics simulations indicate that the generated molecules maintain both structural stability and key interactions comparable to those of a bioactive reference ligand. In addition, the molecular mechanics generalized Born surface area (MM/GBSA) calculations based on MD trajectories suggest that several generated molecules may exhibit relatively favorable binding tendencies compared with the reference. The implementation of the DiffPharma, including code and an execution environment on Google Colab, is available under the MIT license at GitHub: https://github.com/sekijima-lab/DiffPharma .
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.